BLFS vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BLFS exhibits a weak fundamental health profile with a Piotroski F-Score of 2/9, indicating significant financial distress risks, and lacks an Altman Z-Score for further validation. Despite strong revenue growth of 31.2% and improving earnings surprises in recent quarters, profitability remains negative with negative ROE and ROA. The stock trades at a high valuation with a Forward P/E of 155.44 and Price/Sales of 11.96, above sector averages, while insider selling activity raises caution. Analysts maintain a strong_buy consensus, but this is not yet supported by robust cash flow or consistent earnings generation.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BLFS vs JNJ: Head-to-Head Comparison
This page compares BioLife Solutions, Inc. (BLFS) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.